|Dr. Peter A. Altman||CEO, Pres & Director||360k||N/A||1967|
|Mr. David McClung||Chief Financial Officer||300k||N/A||1963|
|Mr. Phil Pesta||VP of Operations||235k||N/A||1966|
|Dr. Eric Henricus J. Duckers||Chief Medical Officer||350k||N/A||1968|
|Dr. Ian McNiece Ph.D.||Chief Scientific Officer||N/A||N/A||1954|
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.